The authors suggested that the group with high CD274 expression on tumor and immune cells and with high levels of tumor-infiltrating cells could benefit from immunotherapy, compared to CD274 negative and with low immune cells CRC. The gene discussed is CD274; the disease is colorectal carcinoma.